Cargando…

IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas

BACKGROUND: Vascular gene expression patterns in lower-grade gliomas (LGGs; diffuse World Health Organization [WHO] grades II–III gliomas) have not been thoroughly investigated. The aim of this study was to molecularly characterize LGG vessels and determine if tumor isocitrate dehydrogenase (IDH) mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lei, He, Liqun, Lugano, Roberta, Roodakker, Kenney, Bergqvist, Michael, Smits, Anja, Dimberg, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176806/ https://www.ncbi.nlm.nih.gov/pubmed/29846705 http://dx.doi.org/10.1093/neuonc/noy088

Ejemplares similares

ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma
por: Huang, Hua, et al.
Publicado: (2021)

Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression
por: Givechian, Kevin B, et al.
Publicado: (2020)

Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
por: Alghamri, Mahmoud S, et al.
Publicado: (2020)

Multicellular “hotspots” harbor high-grade potential in lower-grade gliomas
por: Kirby, Alastair J, et al.
Publicado: (2021)

Establishment of patient-derived organoid models of lower-grade glioma
por: Abdullah, Kalil G, et al.
Publicado: (2021)

Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma
por: Jones, Lindsey E, et al.
Publicado: (2020)

Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
por: van Garderen, Karin A, et al.
Publicado: (2023)

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures
por: Verheul, Cassandra, et al.
Publicado: (2021)

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks
por: Li, Kay Ka-Wai, et al.
Publicado: (2019)

Monitoring response to a clinically relevant IDH inhibitor in glioma—Hyperpolarized (13)C magnetic resonance spectroscopy approaches
por: Hong, Donghyun, et al.
Publicado: (2023)

Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning
por: van der Voort, Sebastian R, et al.
Publicado: (2022)

Environmental and sex-specific molecular signatures of glioma causation
por: Claus, Elizabeth B, et al.
Publicado: (2021)

Distinct metabolic hallmarks of WHO classified adult glioma subtypes
por: Björkblom, Benny, et al.
Publicado: (2022)

High-throughput microRNA profiling of pediatric high-grade gliomas
por: Miele, Evelina, et al.
Publicado: (2014)

An affinity for brainstem microglia in pediatric high-grade gliomas of brainstem origin
por: Zats, Liat Peretz, et al.
Publicado: (2022)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma
por: Brighi, Caterina, et al.
Publicado: (2020)

Parents’ experiences of postmortem tumor donation for high-grade gliomas: benefits and suggested improvements
por: Robertson, Eden G, et al.
Publicado: (2021)

MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network
por: Chakrabarty, Satrajit, et al.
Publicado: (2023)

Gliomas display distinct sex-based differential methylation patterns based on molecular subtype
por: Johansen, Mette L, et al.
Publicado: (2020)

Structural gray matter alterations in glioblastoma and high-grade glioma—A potential biomarker of survival
por: Lamichhane, Bidhan, et al.
Publicado: (2023)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgery
por: Schatlo, Bawarjan, et al.
Publicado: (2015)

The natural compound obtusaquinone targets pediatric high-grade gliomas through ROS-mediated ER stress
por: Teng, Jian, et al.
Publicado: (2020)

Transitioning to molecular diagnostics in pediatric high-grade glioma: experiences with the 2016 WHO classification of CNS tumors
por: Baugh, Joshua N, et al.
Publicado: (2021)

IDH mutation-specific radiomic signature in lower-grade gliomas
por: Liu, Xing, et al.
Publicado: (2019)

Deep proteome investigation of high-grade gliomas reveals heterogeneity driving differential metabolism of 5-aminolevulinic acid
por: Ghantasala, Saicharan, et al.
Publicado: (2023)

Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay
por: Shuford, Stephen, et al.
Publicado: (2021)

Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients
por: Izquierdo, Elisa, et al.
Publicado: (2021)

Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation
por: de Andrade Costa, Amanda, et al.
Publicado: (2021)

Pediatric high-grade gliomas and the WHO CNS Tumor Classification—Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updates
por: Gielen, Gerrit H, et al.
Publicado: (2022)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Early-onset grade 2-3 diffuse gliomas and schwannomas increase the risk of central nervous system tumors among the patients’ relatives
por: Alanen, Eljas, et al.
Publicado: (2023)

Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors
por: Kashani, Elham, et al.
Publicado: (2022)

Pharmacoresistant seizures and IDH mutation in low-grade gliomas
por: Correia, Carlos Eduardo, et al.
Publicado: (2021)

TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors
por: Cantero, Diana, et al.
Publicado: (2020)

Pediatric glioma and medulloblastoma risk and population demographics: a Poisson regression analysis
por: Muskens, Ivo S, et al.
Publicado: (2020)

Glioma-associated microglia/macrophages augment tumorigenicity in canine astrocytoma, a naturally occurring model of human glioma
por: Toedebusch, Ryan, et al.
Publicado: (2021)

Long-lived tumor-associated macrophages in glioma
por: Georgieva, Petya B, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_blj817nj63oo34dtco7q0ro8it